WASHINGTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced full clinical trial results from a pivotal Phase 3 study evaluating cobicistat, a pharmacoenhancing or boosting agent f…
Gilead Sciences filed with the FDA to market "boosting" agent cobicistat, which increases the blood level of some protease in -More- …
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the Marketing Authorisation Application (MAA) for cobicistat, submitted on April 26, 2012, has been vali…
